Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to firstname.lastname@example.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 09 January 2017 | By Zachary Brennan
Galena Biopharma on Monday disclosed in an SEC filing that the US Attorney’s Office for the District of New Jersey and the US Department of Justice (DOJ) are pursuing a criminal investigation, in addition to a previously announced civil investigation, related to the marketing and promotion of its deadly opioid Abstral (fentanyl), which the company sold for $8 million upfront in 2015.
The details of the criminal investigation have not been disclosed.
“There also have been federal and state investigations of a company that has a product that competes with Abstral in the same therapeutic class, and we have learned that the FDA and other governmental agencies are investigating our Abstral promotion practices,” Galena said in its filing.
This announcement follows the company’s receipt of a subpoena issued by the New Jersey office in December 2015, requesting the production of a broad range of documents pertaining to the marketing and promotion of Abstral.
And this was followed by a federal investigation of two high-prescribing physicians for Abstral, which later resulted in the criminal prosecution of the two physicians for alleged violations of the federal False Claims Act and other federal statutes. The criminal trial began on 4 January 2017.
“We have received a trial subpoena for documents in connection with that investigation and we have been in contact with the U.S. Attorney’s Office for the Southern District of Alabama, which is handling the criminal trial, and are cooperating in the production of documents,” Galena added.
The news from Galena comes as DOJ has been cracking down on illegal promotions and bribes linked to the prescribing of fentanyl-based pain medications, which are contributing to a growing number of overdoses and fatalities.
In December, several pharmaceutical executives and managers, formerly employed by Insys Therapeutics, were arrested on charges that they led a nationwide conspiracy to bribe medical practitioners to unnecessarily prescribe a fentanyl-based pain medication and defraud health insurers.
In June, former pharmaceutical company employees were also arrested for participating in a fentanyl kickback scheme.
Tags: Galena, DOJ, Abstral, fentanyl marketing